Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | GLA | P06280 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ME2 | P23368 | 1/20 | 0.55 |
| ▸ | ME1 | P48163 | 1/20 | 0.55 |
| ▸ | ME3 | Q16798 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | STAT6 | P42226 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3619455 | 0.86 | GPR35 (0.61) | CYP1A2HSD17B10CYP2C19KDM4EALDH1A1 | |
| SCHEMBL29379734 | 0.86 | GPR35 (0.61) | CYP1A2HSD17B10CYP2C19KDM4EALDH1A1 | |
| Zinc Ion SCHEMBL2858466 | 0.83 | GPR35 (0.46) | CYP1A2HSD17B10CYP2C19KDM4EALDH1A1 | |
| SCHEMBL770722 | 0.82 | CYP1A2 (0.70) | CYP1A2HSD17B10CYP2C19KDM4EALDH1A1 | |
| SCHEMBL29779946 | 0.80 | CYP1A2 (0.68) | CYP1A2HSD17B10CYP2C19KDM4EALDH1A1 | |
| SCHEMBL88986 | 0.80 | CYP1A2 (0.68) | CYP1A2HSD17B10CYP2C19KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL11313207 | 0.79 | CYP1A2 (0.66) | CYP1A2HSD17B10CYP2C19KDM4EALDH1A1 | |
| SCHEMBL6036146 | 0.77 | CYP1A2 (0.63) | CYP1A2HSD17B10CYP2C19KDM4EALDH1A1 | |
| SCHEMBL28146524 | 0.77 | MEN1 (0.63) | CYP1A2HSD17B10CYP2C19KDM4EALDH1A1 | |
| SCHEMBL4731723 | 0.77 | ME2 (0.73) | CYP1A2HSD17B10CYP2C19KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1921 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346342-B1 | METHOD TO SEPARATE LIPIDS FROM CHEESE WHEY AND FAT-FREE WHEY PROTEIN PRODUCT FORMED THEREBY | WISCONSIN ALUMNI RES FOUND (US) | 2015-09-09 | — | — | EP | claimed |
| US-8658649-B2 | Kinase inhibitor | SANOFI (FR) | 2014-02-25 | — | — | US | claimed |
| EP-2094708-B1 | A PYRROLOPYRAZIN AS SYK-KINASE INHIBITOR | SANOFI SA (FR) | 2013-10-23 | — | — | EP | claimed |
| US-20100035884-A1 | KINASE INHIBITOR | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | claimed |
| US-12037327-B2 | Compounds and methods targeting GPER for treatment of diseases associated with calcium | SAINT LOUIS UNIVERSITY (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240228528-A1 | 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | Reata Pharmaceuticals Holdings, LLC (US) | 2024-07-11 | — | — | US | disclosed |
| CN-118286388-A | Application of cyclosporin in treating intestinal radiation injury | 中国人民解放军军事科学院军事医学研究院 | 2024-07-05 | — | — | CN | disclosed |
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY | 2024-06-27 | — | — | US | disclosed |
| US-12016896-B2 | Dipeptidomimetics as inhibitors of human immunoproteasomes | CORNELL UNIVERSITY (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240197730-A1 | CANCER TREATMENT USING PARP INHIBITORS AND PLK1 INHIBITORS | CARDIFF ONCOLOGY, INC. | 2024-06-20 | — | — | US | disclosed |
| EP-3538101-B1 | INHIBITORS OF CANCER AND/OR METASTASIS | UNIV VIRGINIA COMMONWEALTH (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-4385498-A1 | PHARMACEUTICAL PREPARATION, PREPARATION METHOD THEREFOR AND USE THEREOF | Coherent Biopharma (Suzhou), Limited (CN) | 2024-06-19 | — | — | EP | disclosed |
| US-5236940-A | Administering for treatment of medical conditions associated with the effects of glutamate; glutamate-induced convulsions; schizophrenia; sleep disorders | RHONE-POULENC SANTE (FR) | 1993-08-17 | — | — | US | disclosed |
| US-5068238-A | Anticonvulsants, schizophrenia, sleep disorders, antiischemia agents and cognition activators | RHONE-POULENC SANTE (FR) | 1991-11-26 | — | — | US | disclosed |
| US-5008280-A | Treatment of glutamate-induced convulsions, schizophrenia | RHONE-POULENC SANTE (FR) | 1991-04-16 | — | — | US | disclosed |
| US-4956362-A | Use of carpipramine for the treatment of anxiety and sleep disorders | Rhone-Poulenc Sante, a French Body Corporate (FR) | 1990-09-11 | — | — | US | disclosed |
| US-4916119-A | IMMUNOSTIMULANT TRIPEPTIDES | RHONE-POULENC INDUSTRIES (FR) | 1990-04-10 | — | — | US | disclosed |
| EP-0174833-A2 | Triazoloquinoline derivatives | MAY & BAKER LIMITED (GB) | 1986-03-19 | — | — | EP | disclosed |
| EP-0174832-A2 | Ethene derivatives | MAY & BAKER LIMITED (GB) | 1986-03-19 | — | — | EP | disclosed |
| US-4000306-A | Anti-arrhythmic compositions containing isoindoline derivatives | RHONE-POULENC S.A. (FR) | 1976-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197730-A1 | CANCER TREATMENT USING PARP INHIBITORS AND PLK1 INHIBITORS | PLK1, PLK2, CHEK1 | CYP1A2 4333/4885HSD17B10 3372/4885CYP2C19 2500/4885 |
| US-20240228528-A1 | 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | CYP2A13, CYP4B1, CYP4A22 | CYP1A2 36/4885HSD17B10 348/4885CYP2C19 35/4885 |
| US-20100035884-A1 | KINASE INHIBITOR | MAP3K1, MAP3K20, MAP3K19 | CYP1A2 1027/4885HSD17B10 2075/4885CYP2C19 685/4885 |
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | OPRM1, OPRK1, CCR5 | CYP1A2 1252/4885HSD17B10 1528/4885CYP2C19 2166/4885 |
| US-12037327-B2 | Compounds and methods targeting GPER for treatment of diseases associated with calcium | GPER1, GPBAR1, GRPR | CYP1A2 1828/4885HSD17B10 1671/4885CYP2C19 2716/4885 |
| US-12016896-B2 | Dipeptidomimetics as inhibitors of human immunoproteasomes | PREP, CTSC, DNPEP | CYP1A2 2755/4885HSD17B10 3798/4885CYP2C19 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.